Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Tanshinones: An Update in the Medicinal Chemistry in Recent 5 Years

Author(s): Zhencheng Lai, Jixiao He, Changxin Zhou, Huajun Zhao and Sunliang Cui*

Volume 28, Issue 14, 2021

Published on: 21 May, 2020

Page: [2807 - 2827] Pages: 21

DOI: 10.2174/0929867327666200521124850

Price: $65

Abstract

Tanshinones are an important type of natural products isolated from Salvia miltiorrhiza Bunge with various bioactivities. Tanshinone IIa, cryptotanshinone and tanshinone I are three kinds of tanshinones which have been widely investigated. Particularly, sodium tanshinone IIa sulfonate is a water-soluble derivative of tanshinone IIa and it is used in clinical in China for treating cardiovascular diseases. In recent years, there are increasing interests in the investigation of tanshinones derivatives in various diseases. This article presents a review of the anti-atherosclerotic effects, cardioprotective effects, anticancer activities, antibacterial activities and antiviral activities of tanshinones and structural modification work in recent years.

Keywords: Tanshinone, structural modification, anti-atherosclerotic effects, cardioprotective effects, anticancer activities, antibacterial activities, antiviral activities.

« Previous Next »
[1]
Mohammadhosseini, M.; Pazoki, A.; Akhlaghi, H. Chemical composition of the essential oils from flowers, stems, and roots of Salvia multicaulis growing wild in Iran. Chem. Nat. Compd., 2008, 44, 127-128.
[http://dx.doi.org/10.1007/s10600-008-0039-3]
[2]
Vallejo, M.C.G.; Moujir, L.; Burillo, J.; Guerra, L.L.; González, M.; Peñate, R.D.; Andrés, L.S.; Luis, J.G.; Blanco, F.L.; de Galarreta, C.M. Ruiz. Chemical composition and biological activities of the essential oils of Salvia canariensis. Flavour Fragrance J., 2006, 21, 72-76.
[http://dx.doi.org/10.1002/ffj.1504]
[3]
Wu, Y.B.; Ni, Z.Y.; Shi, Q.W.; Dong, M.; Kiyota, H.; Gu, Y.C.; Cong, B. Constituents from Salvia species and their biological activities. Chem. Rev., 2012, 112(11), 5967-6026.
[http://dx.doi.org/10.1021/cr200058f] [PMID: 22967178]
[4]
Wang, B. Salvia miltiorrhiza: Chemical and pharmacological review of a medicinal plant. J. Med. Plants Res., 2010, 4, 2813-2821.
[5]
Zhou, L.; Zuo, Z.; Chow, M.S.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol., 2005, 45(12), 1345-1359.
[http://dx.doi.org/10.1177/0091270005282630] [PMID: 16291709]
[6]
Chen, X.; Guo, J.; Bao, J.; Lu, J.; Wang, Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med. Res. Rev., 2014, 34(4), 768-794.
[http://dx.doi.org/10.1002/med.21304] [PMID: 24123144]
[7]
Li, Z.M.; Xu, S.W.; Liu, P.Q. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol. Sin., 2018, 39(5), 802-824.
[http://dx.doi.org/10.1038/aps.2017.193] [PMID: 29698387]
[8]
Dong, Y.; Morris-Natschke, S.L.; Lee, K.H. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat. Prod. Rep., 2011, 28(3), 529-542.
[http://dx.doi.org/10.1039/c0np00035c] [PMID: 21225077]
[9]
Tian, X.H.; Wu, J.H. Tanshinone derivatives: a patent review (January 2006 - September 2012). Expert Opin. Ther. Pat., 2013, 23(1), 19-29.
[http://dx.doi.org/10.1517/13543776.2013.736494] [PMID: 23094864]
[10]
Du, J.R.; Li, X.; Zhang, R.; Qian, Z.M. Tanshinone inhibits intimal hyperplasia in the ligated carotid artery in mice. J. Ethnopharmacol., 2005, 98(3), 319-322.
[http://dx.doi.org/10.1016/j.jep.2005.01.038] [PMID: 15814266]
[11]
Li, X.; Du, J.R.; Yu, Y.; Bai, B.; Zheng, X.Y. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. J. Ethnopharmacol., 2010, 129(2), 273-279.
[http://dx.doi.org/10.1016/j.jep.2010.03.021] [PMID: 20363310]
[12]
Chen, W.; Tang, F.; Xie, B.; Chen, S.; Huang, H.; Liu, P. Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur. J. Pharmacol., 2012, 674(2-3), 359-364.
[http://dx.doi.org/10.1016/j.ejphar.2011.10.040] [PMID: 22088276]
[13]
Fang, Z.Y.; Lin, R.; Yuan, B.X.; Liu, Y.; Zhang, H. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci., 2007, 81(17-18), 1339-1345.
[http://dx.doi.org/10.1016/j.lfs.2007.08.043] [PMID: 17942126]
[14]
Liu, X.; Guo, C.Y.; Ma, X.J.; Wu, C.F.; Zhang, Y.; Sun, M.Y.; Pan, Y.T.; Yin, H.J. Anti-inflammatory effects of tanshinone IIA on atherosclerostic vessels of ovariectomized ApoE mice are mediated by estrogen receptor activation and through the ERK signaling pathway. Cell. Physiol. Biochem., 2015, 35(5), 1744-1755.
[http://dx.doi.org/10.1159/000373986 ] [PMID: 25832326]
[15]
Liu, Z.; Wang, J.; Huang, E.; Gao, S.; Li, H.; Lu, J.; Tian, K.; Little, P.J.; Shen, X.; Xu, S.; Liu, P. Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. J. Lipid Res., 2014, 55(2), 201-213.
[http://dx.doi.org/10.1194/jlr.M040394] [PMID: 24302760]
[16]
Tang, F.; Wu, X.; Wang, T.; Wang, P.; Li, R.; Zhang, H.; Gao, J.; Chen, S.; Bao, L.; Huang, H.; Liu, P. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul. Pharmacol., 2007, 46(6), 427-438.
[http://dx.doi.org/10.1016/j.vph.2007.01.001] [PMID: 17337361]
[17]
Tang, F.T.; Cao, Y.; Wang, T.Q.; Wang, L.J.; Guo, J.; Zhou, X.S.; Xu, S.W.; Liu, W.H.; Liu, P.Q.; Huang, H.Q. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur. J. Pharmacol., 2011, 650(1), 275-284.
[http://dx.doi.org/10.1016/j.ejphar.2010.07.038] [PMID: 20854809]
[18]
Xu, S.; Little, P.J.; Lan, T.; Huang, Y.; Le, K.; Wu, X.; Shen, X.; Huang, H.; Cai, Y.; Tang, F.; Wang, H.; Liu, P. Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch. Biochem. Biophys., 2011, 515(1-2), 72-79.
[http://dx.doi.org/10.1016/j.abb.2011.08.006] [PMID: 21889487]
[19]
Xu, S.; Liu, Z.; Huang, Y.; Chen, J.; Chen, S.; Shen, X.; Huang, H.; Liu, P. Effectiveness of combination therapy of atorvastatin and non-lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis. Int. J. Cardiol., 2014, 174(3), 878-880.
[http://dx.doi.org/10.1016/j.ijcard.2014.04.226] [PMID: 24814901]
[20]
Zhao, D.; Tong, L.; Zhang, L.; Li, H.; Wan, Y.; Zhang, T. Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice. Mol. Med. Rep., 2016, 14(6), 4983-4990.
[http://dx.doi.org/10.3892/mmr.2016.5916] [PMID: 27840935]
[21]
Zhu, J.; Xu, Y.; Ren, G.; Hu, X.; Wang, C.; Yang, Z.; Li, Z.; Mao, W.; Lu, D.; Tanshinone, I.I.A. Tanshinone IIA Sodium sulfonate regulates antioxidant system, inflammation, and endothelial dysfunction in atherosclerosis by downregulation of CLIC1. Eur. J. Pharmacol., 2017, 815, 427-436.
[http://dx.doi.org/10.1016/j.ejphar.2017.09.047] [PMID: 28970012]
[22]
Shang, T.; Liu, Z.; Zhou, M.; Zarins, C.K.; Xu, C.; Liu, C.J. Inhibition of experimental abdominal aortic aneurysm in a rat model by way of tanshinone IIA. J. Surg. Res., 2012, 178(2), 1029-1037.
[http://dx.doi.org/10.1016/j.jss.2012.04.068] [PMID: 22640888]
[23]
Niu, X.L.; Ichimori, K.; Yang, X.; Hirota, Y.; Hoshiai, K.; Li, M.; Nakazawa, H. Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radic. Res., 2000, 33(3), 305-312.
[http://dx.doi.org/10.1080/10715760000301471] [PMID: 10993484]
[24]
Bi, X.; Zhang, K.; He, L.; Gao, B.; Gu, Q.; Li, X.; Chen, J.; Wang, J. Synthesis and biological evaluation of tanshinone IIA derivatives as novel endothelial protective agents. Future Med. Chem., 2017, 9(10), 1073-1085.
[http://dx.doi.org/10.4155/fmc-2016-0241] [PMID: 28632415]
[25]
Chang, C.C.; Chu, C.F.; Wang, C.N.; Wu, H.T.; Bi, K.W.; Pang, J.H.S.; Huang, S.T. The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-α-induced VCAM-1, ICAM-1 and CX3CL1 expression. Phytomedicine, 2014, 21, 207-216.
[http://dx.doi.org/10.1016/j.phymed.2013.09.012 ] [PMID: 24157079]
[26]
Nizamutdinova, I.T.; Kim, Y.M.; Jin, H.; Son, K.H.; Lee, J.H.; Chang, K.C.; Kim, H.J. Tanshinone IIA inhibits TNF-α-mediated induction of VCAM-1 but not ICAM-1 through the regulation of GATA-6 and IRF-1. Int. Immunopharmacol., 2012, 14(4), 650-657.
[http://dx.doi.org/10.1016/j.intimp.2012.09.017] [PMID: 23085565]
[27]
Tang, C.; Xue, H.L.; Bai, C-L.; Fu, R. Regulation of adhesion molecules expression in TNF-α-stimulated brain microvascular endothelial cells by tanshinone IIA: involvement of NF-κB and ROS generation. Phytother. Res., 2011, 25(3), 376-380.
[http://dx.doi.org/10.1002/ptr.3278] [PMID: 20687137]
[28]
Li, Y.H.; Xu, Q.; Xu, W.H.; Guo, X.H.; Zhang, S.; Chen, Y-D. Mechanisms of protection against diabetes-induced impairment of endothelium-dependent vasorelaxation by Tanshinone IIA. Biochim. Biophys. Acta, 2015, 1850(4), 813-823.
[http://dx.doi.org/10.1016/j.bbagen.2015.01.007] [PMID: 25613563]
[29]
Chen, L.; Guo, Q.H.; Chang, Y.; Zhao, Y.S.; Li, A.Y.; Ji, E.S. Tanshinone IIA ameliorated endothelial dysfunction in rats with chronic intermittent hypoxia. J. Soc. Cardiovasc. Pathol., 2017, 31, 47-53.
[http://dx.doi.org/10.1016/j.carpath.2017.06.008] [PMID: 28985491]
[30]
Zhou, Z.W.; Xie, X.L.; Zhou, S.F.; Li, C.G. Mechanism of reversal of high glucose-induced endothelial nitric oxide synthase uncoupling by tanshinone IIA in human endothelial cell line EA.hy926. Eur. J. Pharmacol., 2012, 697(1-3), 97-105.
[http://dx.doi.org/10.1016/j.ejphar.2012.09.051] [PMID: 23063542]
[31]
Maione, F.; De Feo, V.; Caiazzo, E.; De Martino, L.; Cicala, C.; Mascolo, N. Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway. J. Ethnopharmacol., 2014, 155(2), 1236-1242.
[http://dx.doi.org/10.1016/j.jep.2014.07.010] [PMID: 25038434]
[32]
Wang, Y.; Li, J.X.; Wang, Y.Q.; Miao, Z.H. Tanshinone I inhibits tumor angiogenesis by reducing Stat3 phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. Oncotarget, 2015, 6(18), 16031-16042.
[http://dx.doi.org/10.18632/oncotarget.3648] [PMID: 26202747]
[33]
Huang, B.; Zhou, Z.Y.; Li, S.; Huang, X.H.; Tang, J.Y.; Hoi, M.P.M.; Lee, S.M.Y. Tanshinone I prevents atorvastatin-induced cerebral hemorrhage in zebrafish and stabilizes endothelial cell-cell adhesion by inhibiting VE-cadherin internalization and actin-myosin contractility. Pharmacol. Res., 2018, 128, 389-398.
[http://dx.doi.org/10.1016/j.phrs.2017.09.025] [PMID: 29017932]
[34]
Ahmad, Z.; Ng, C.T.; Fong, L.Y.; Bakar, N.A.A.; Hussain, N.H.M.; Ang, K.P.; Ee, G.C.L.; Hakim, M.N. Cryptotanshinone inhibits TNF-α-induced early atherogenic events in vitro. J. Physiol. Sci., 2016, 66(3), 213-220.
[http://dx.doi.org/10.1007/s12576-015-0410-7] [PMID: 26732386]
[35]
Liu, Z.; Xu, S.; Huang, X.; Wang, J.; Gao, S.; Li, H.; Zhou, C.; Ye, J.; Chen, S.; Jin, Z.G.; Liu, P. Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1). Br. J. Pharmacol., 2015, 172(23), 5661-5675.
[http://dx.doi.org/10.1111/bph.13068] [PMID: 25572313]
[36]
Zhao, W.; Wu, C.; Chen, X. Cryptotanshinone inhibits oxidized LDL-induced adhesion molecule expression via ROS dependent NF-κB pathways. Cell Adhes. Migr., 2016, 10(3), 248-258.
[http://dx.doi.org/10.1080/19336918.2015.1119361] [PMID: 26647279]
[37]
Suh, S.J.; Jin, U.H.; Choi, H.J.; Chang, H.W.; Son, J.K.; Lee, S.H.; Jeon, S.J.; Son, K.H.; Chang, Y.C.; Lee, Y.C.; Kim, C.H. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem. Pharmacol., 2006, 72(12), 1680-1689.
[http://dx.doi.org/10.1016/j.bcp.2006.08.013] [PMID: 16999937]
[38]
Ma, S.; Zhang, D.; Lou, H.; Sun, L.; Ji, J. Evaluation of the anti-inflammatory activities of tanshinones isolated from Salvia miltiorrhiza var. alba roots in THP-1 macrophages. J. Ethnopharmacol., 2016, 188, 193-199.
[http://dx.doi.org/10.1016/j.jep.2016.05.018] [PMID: 27178632]
[39]
Zhou, G.; Jiang, W.; Zhao, Y.; Ma, G.; Xin, W.; Yin, J.; Zhao, B. Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. Biochem. Pharmacol., 2003, 65(1), 51-57.
[http://dx.doi.org/10.1016/S0006-2952(02)01447-8] [PMID: 12473378 ]
[40]
Wei, B.; You, M.G.; Ling, J.J.; Wei, L.L.; Wang, K.; Li, W.W.; Chen, T.; Du, Q.M.; Ji, H. Regulation of antioxidant system, lipids and fatty acid β-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis, 2013, 230(1), 148-156.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.07.005] [PMID: 23958267]
[41]
Hu, Q.; Wei, B.; Wei, L.; Hua, K.; Yu, X.; Li, H.; Ji, H. Sodium tanshinone IIA sulfonate ameliorates ischemia-induced myocardial inflammation and lipid accumulation in Beagle dogs through NLRP3 inflammasome. Int. J. Cardiol., 2015, 196, 183-192.
[http://dx.doi.org/10.1016/j.ijcard.2015.05.152] [PMID: 26143630]
[42]
Ren, Z.H.; Tong, Y.H.; Xu, W.; Ma, J.; Chen, Y. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine, 2010, 17(3-4), 212-218.
[http://dx.doi.org/10.1016/j.phymed.2009.08.010] [PMID: 19800776]
[43]
Gu, Y.; Liang, Z.; Wang, H.; Jin, J.; Zhang, S.; Xue, S.; Chen, J.; He, H.; Duan, K.; Wang, J.; Chang, X.; Qiu, C. Tanshinone IIA protects H9c2 cells from oxidative stress-induced cell death via microRNA-133 upregulation and Akt activation. Exp. Ther. Med., 2016, 12(2), 1147-1152.
[http://dx.doi.org/10.3892/etm.2016.3400] [PMID: 27446335]
[44]
Yang, R.; Liu, A.; Ma, X.; Li, L.; Su, D.; Liu, J. Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J. Cardiovasc. Pharmacol., 2008, 51(4), 396-401.
[http://dx.doi.org/10.1097/FJC.0b013e3181671439] [PMID: 18427283]
[45]
Shan, H.; Li, X.; Pan, Z.; Zhang, L.; Cai, B.; Zhang, Y.; Xu, C.; Chu, W.; Qiao, G.; Li, B.; Lu, Y.; Yang, B. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br. J. Pharmacol., 2009, 158(5), 1227-1235.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00377.x] [PMID: 19775284]
[46]
Jin, H.J.; Xie, X.L.; Ye, J.M.; Li, C.G. TanshinoneIIA and cryptotanshinone protect against hypoxia-induced mitochondrial apoptosis in H9c2 cells. PLoS One, 2013, 8(1)e51720
[http://dx.doi.org/10.1371/journal.pone.0051720] [PMID: 23341883]
[47]
Hong, H.J.; Liu, J.C.; Cheng, T.H.; Chan, P. Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes. Acta Pharmacol. Sin., 2010, 31(12), 1569-1575.
[http://dx.doi.org/10.1038/aps.2010.176] [PMID: 21102479]
[48]
Wei, B.; Li, W.W.; Ji, J.; Hu, Q.H.; Ji, H. The cardioprotective effect of sodium tanshinone IIA sulfonate and the optimizing of therapeutic time window in myocardial ischemia/reperfusion injury in rats. Atherosclerosis, 2014, 235(2), 318-327.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.924] [PMID: 24911635]
[49]
Hu, H.; Zhai, C.; Qian, G.; Gu, A.; Liu, J.; Ying, F.; Xu, W.; Jin, D.; Wang, H.; Hu, H.; Zhang, Y.; Tang, G. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharm. Biol., 2015, 53(12), 1752-1758.
[http://dx.doi.org/10.3109/13880209.2015.1005753] [PMID: 25864557]
[50]
Zhang, Y.; Wei, L.; Sun, D.; Cao, F.; Gao, H.; Zhao, L.; Du, J.; Li, Y.; Wang, H. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes. Metab., 2010, 12(4), 316-322.
[http://dx.doi.org/10.1111/j.1463-1326.2009.01166.x] [PMID: 20380652]
[51]
Pan, Y.; Qian, J.X.; Lu, S.Q.; Chen, J.W.; Zhao, X.D.; Jiang, Y.; Wang, L-H.; Zhang, G-X. Protective effects of tanshinone IIA sodium sulfonate on ischemia-reperfusion-induced myocardial injury in rats. Iran. J. Basic Med. Sci., 2017, 20(3), 308-315.
[http://dx.doi.org/10.22038/ijbms.2017.8361] [PMID: 28392904]
[52]
Zhang, M.Q.; Zheng, Y.L.; Chen, H.; Tu, J.F.; Shen, Y.; Guo, J.P.; Yang, X.H.; Yuan, S.R.; Chen, L.Z.; Chai, J.J.; Lu, J.H.; Zhai, C.L. Sodium tanshinone IIA sulfonate protects rat myocardium against ischemia-reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway. Acta Pharmacol. Sin., 2013, 34(11), 1386-1396.
[http://dx.doi.org/10.1038/aps.2013.91] [PMID: 24077633]
[53]
Zhang, M.Q.; Tu, J.F.; Chen, H.; Shen, Y.; Pang, L.X.; Yang, X.H.; Sun, R.H.; Zheng, Y.L. Janus kinase/signal transducer and activator of transcription inhibitors enhance the protective effect mediated by tanshinone IIA from hypoxic/ischemic injury in cardiac myocytes. Mol. Med. Rep., 2015, 11(4), 3115-3121.
[http://dx.doi.org/10.3892/mmr.2014.3063] [PMID: 25502794]
[54]
Fu, Y.; Chen, J. Synthesis and application of sulfonamide compounds. Patent number: CN104341481A, 2015.
[55]
Fu, Y.; Chen, J. Synthesis and pharmaceutical application of sulfamide derivative. CN104341450A, 2015 11February;
[56]
Wang, J.; Chen, J.; He, L. Use of tanshinone IIA derivatives in preparation of drug for protecting endothelial cells. Patent number: CN105837538A, 2016.
[57]
Ding, L.; Wang, J.; Huang, Z. Application of tanshinone II A derivative in drugs. Patent number: CN105884856A, 2016.
[58]
Chen, J. Tanshinone IIA phosphoric acid derivative and synthesis and use thereof as medicine. Patent number: CN106478764A, 2017.
[59]
Chen, J. Sulfotanshinone IIA derivatives, and synthesis and applications thereof as drug. Patent number: CN106478765A, 2017.
[60]
Bi, Y.; Wang, Z. Danproone compound 15-site amide derivative, and preparation process and application thereof. Patent number: CN106831934A, 2017.
[61]
Sun, Q.; Zhang, W.; Yuan, H. Water-soluble tanshinone II A derivative, preparation and application thereof. Patent number: CN107540725A, 2018.
[62]
Qin, Y.L.; Chen, L.; He, W.; Su, M.; Jin, Q.; Fang, Z.; Ouyang, P.K.; Guo, K. Continuous synthesis and anti-myocardial injury of tanshinone IIA derivatives. J. Asian Nat. Prod. Res., 2018, 20(2), 139-147.
[http://dx.doi.org/10.1080/10286020.2017.1337751] [PMID: 28595458]
[63]
Su, M.; Wang, W. Tanshinone IIA derivative and preparation method thereof. Patent number: CN107663224A, 2018.
[64]
Tan, H.; Li, W.; Tang, A. Synthesis and application of tanshinone IIA derivatives. Patent number: CN109369771A, 2019.
[65]
Song, W.Y.; Liu, Y.; Yu, W.; Mu, J.; Yin, B.; Zuo, C.; Wei, H.; Zhang, R. Tanshinone IIA piperazine compounds as well as preparation method and application thereof. Patent number: CN110016069A, 2019.
[66]
Gimbrone, M.A. Jr; García-Cardeña, G. Endothelial cell dysfunction and the Pathobiology of atherosclerosis. Circ. Res., 2016, 118(4), 620-636.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306301] [PMID: 26892962]
[67]
Huang, C.S.; Song, Y.R.; Huang, Q. L. Tanshinone IIA thiophene pyridine compound and preparation method and application thereof Tanshinone IIA thiophene pyridine compound and preparation method and application thereof. Patent number: CN110066310A, 2019.
[68]
Zhang, B.; Shi, L.; Liu, S.; Guo, R. Tanshinone IIA derivate comprising polyethylene glycol group and preparation and application of tanshinone IIA derivate. Patent number: CN105037484A, 2015.
[69]
Wang, J.; Gong, Z. Application of tanshinone IIA derivative in preparation of ischemic stroke drugs. Patent number: CN109908154A, 2019.
[70]
Zhang, Q.; Zhu, Y.; Liu, X.; Zhou, Y. 9-hydroxytanshinone IIA sodium sulfonate ester derivative and medicinal use thereof. Patent number: CN104974216A, 2015.
[71]
Bi, Y.; Wang, Y.; Wu, Z.; Yang, X. 1-tanshinone acid ester derivatives with cardioprotective effect and application of 1- tanshinone acid ester derivatives. Patent number: CN106800582A, 2017.
[72]
Zhao, Y.P.; Wang, F.; Jiang, W.; Liu, J.; Liu, B.L.; Qi, L.W.; Zhou, W. A mitochondrion-targeting tanshinone IIA derivative attenuates myocardial hypoxia reoxygenation injury through a SDH-dependent antioxidant mechanism. J. Drug Target., 2019, 27(8), 896-902.
[http://dx.doi.org/10.1080/1061186X.2019.1566338] [PMID: 30632415]
[73]
Nizamutdinova, I.T.; Lee, G.W.; Son, K.H.; Jeon, S.J.; Kang, S.S.; Kim, Y.S.; Lee, J.H.; Seo, H.G.; Chang, K.C.; Kim, H.J. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int. J. Oncol., 2008, 33(3), 485-491.
[PMID: 18695877]
[74]
Wang, L.; Wu, J.; Lu, J.; Ma, R.; Sun, D.; Tang, J. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. Mol. Med. Rep., 2015, 11(2), 931-939.
[http://dx.doi.org/10.3892/mmr.2014.2819] [PMID: 25355053]
[75]
Su, C.C.; Chen, G-W.; Lin, J-G. Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int. J. Mol. Med., 2008, 22(5), 613-618.
[PMID: 18949381]
[76]
Lee, C.Y.; Sher, H.F.; Chen, H.W.; Liu, C.C.; Chen, C.H.; Lin, C.S.; Yang, P.C.; Tsay, H.S.; Chen, J.J.W. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol. Cancer Ther., 2008, 7(11), 3527-3538.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-2288] [PMID: 19001436]
[77]
Liu, X.D.; Fan, R.F.; Zhang, Y.; Yang, H.Z.; Fang, Z.G.; Guan, W-B.; Lin, D.J.; Xiao, R.Z.; Huang, R.W.; Huang, H.Q.; Liu, P.Q.; Liu, J.J. Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in vitro. Int. J. Mol. Sci., 2010, 11(6), 2267-2280.
[http://dx.doi.org/10.3390/ijms11062267] [PMID: 20640151]
[78]
Shin, E.A.; Sohn, E.J.; Won, G.; Choi, J.U.; Jeong, M.; Kim, B.; Kim, M.J.; Kim, S.H. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget, 2014, 5(14), 5624-5636.
[http://dx.doi.org/10.18632/oncotarget.2152] [PMID: 25015549]
[79]
Yu, H.; Subedi, R.K.; Nepal, P.R.; Kim, Y.G.; Choi, H-K. Enhancement of solubility and dissolution rate of cryptotanshinone, tanshinone I and tanshinone IIA extracted from Salvia miltiorrhiza. Arch. Pharm. Res., 2012, 35(8), 1457-1464.
[http://dx.doi.org/10.1007/s12272-012-0816-1] [PMID: 22941489]
[80]
Liu, Y.; Li, X.; Li, Y.; Wang, L.; Xue, M. Simultaneous determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone I and dihydrotanshinone I by liquid chromatographic-mass spectrometry and the application to pharmacokinetics in rats. J. Pharm. Biomed. Anal., 2010, 53(3), 698-704.
[http://dx.doi.org/10.1016/j.jpba.2010.03.041] [PMID: 20430561]
[81]
Park, E.J.; Ji, H.Y.; Kim, N.J.; Song, W.Y.; Kim, Y.H.; Kim, Y.C.; Sohn, D.H.; Lee, H.S. Simultaneous determination of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study of a standardized fraction of Salvia miltiorrhiza, PF2401-SF. Biomed. Chromatogr., 2008, 22(5), 548-555.
[http://dx.doi.org/10.1002/bmc.968] [PMID: 18205136]
[82]
Qin, Y.L. Preparation of tanshinone I derivatives for pharmaceutical use. Patent number: CN1837200A, 2006.
[83]
Xu, W.; Jiang, C.; Yang, F.; Shen, X.; Li, R.; Xue, D. Preparation of tanshinone derivatives as anti-tumor agents. Patent number: CN103288916A, 2012.
[84]
Jiao, M.; Ding, C.; Zhang, A. Preparation of 2-aryl derivatives of tanshinone I through a palladium-catalyzed Csp2-H activation/arylation approach. Tetrahedron Lett., 2015, 56, 2799-2802.
[http://dx.doi.org/10.1016/j.tetlet.2015.04.040]
[85]
Luan, D.; Qin, L.; Huang, W.; Luan, S. Tanshinone derivative, preparation method and application thereof. Patent number: CN105884723A, 2016.
[86]
Luan, D.; Qin, L.; Luan, S. Tanshinone derivative useful in treatment of various diseases and its preparation. Patent number: CN 105884857A, 2016.
[87]
Jiao, M.; Ding, C.; Zhang, A. Facile construction of 3-hydroxyphenanthrene-1,4-diones: key intermediates to tanshinone I and its A-ring-modified analogue. Tetrahedron, 2014, 70, 2976-2981.
[http://dx.doi.org/10.1016/j.tet.2014.03.019]
[88]
Jin, H.; Li, H.; Mao, S.; Ma, W.; Chen, Y.; Liu, S. Tanshinone I derivatives, synthetic method and antitumor application. Patent number: CN 102702302B, 2014.
[89]
Ding, C.; Tian, Q.; Li, J.; Jiao, M.; Song, S.; Wang, Y.; Miao, Z.; Zhang, A. Structural modification of natural product Tanshinone I leading to discovery of novel nitrogen-enriched derivatives with enhanced anticancer profile and improved drug-like properties. J. Med. Chem., 2018, 61(3), 760-776.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01259] [PMID: 29294282]
[90]
Ding, C.; Song, S.; Jiao, M.; Wang, Y.; Miao, Z.; Zhang, A. Tanshinone I derivative, preparation method and applications thereof Tanshinone I derivative, preparation method and applications thereof. Patent number: CN105622709A, 2016.
[91]
Yoon, Y.; Kim, Y.O.; Jeon, W.K.; Park, H.J.; Sung, H.J. Tanshinone IIA isolated from Salvia miltiorrhiza BUNGE induced apoptosis in HL60 human premyelocytic leukemia cell line. J. Ethnopharmacol., 1999, 68(1-3), 121-127.
[http://dx.doi.org/10.1016/S0378-8741(99)00059-8] [PMID: 10624871]
[92]
Zhou, L.; Chan, W.K.; Xu, N.; Xiao, K.; Luo, H.; Luo, K.Q.; Chang, D.C. Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest. Life Sci., 2008, 83(11-12), 394-403.
[http://dx.doi.org/10.1016/j.lfs.2008.07.011] [PMID: 18721815]
[93]
Wang, J.; Wang, X.; Jiang, S.; Yuan, S.; Lin, P.; Zhang, J.; Lu, Y.; Wang, Q.; Xiong, Z.; Wu, Y.; Ren, J.; Yang, H. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J. Neurooncol., 2007, 82(1), 11-21.
[http://dx.doi.org/10.1007/s11060-006-9242-x] [PMID: 16955220]
[94]
Liu, J.J.; Lin, D.J.; Liu, P.Q.; Huang, M.; Li, X.D.; Huang, R.W. Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J. Biomed. Sci., 2006, 13(6), 813-823.
[http://dx.doi.org/10.1007/s11373-006-9110-x] [PMID: 16955348]
[95]
Liu, J.J.; Zhang, Y.; Lin, D.J.; Xiao, R.Z. Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol. Rep., 2009, 21(4), 1075-1081.
[http://dx.doi.org/10.3892/or_00000326] [PMID: 19288011]
[96]
Yuan, S.L.; Wei, Y.Q.; Wang, X.J.; Xiao, F.; Li, S.F.; Zhang, J. Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J. Gastroenterol., 2004, 10(14), 2024-2028.
[http://dx.doi.org/10.3748/wjg.v10.i14.2024] [PMID: 15237427]
[97]
Sung, H.J.; Choi, S.M.; Yoon, Y.; An, K.S. Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp. Mol. Med., 1999, 31(4), 174-178.
[http://dx.doi.org/10.1038/emm.1999.28] [PMID: 10630370]
[98]
Pan, T.L.; Hung, Y.C.; Wang, P.W.; Chen, S.T.; Hsu, T.K.; Sintupisut, N.; Cheng, C.S.; Lyu, P.C. Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics, 2010, 10(5), 914-929.
[http://dx.doi.org/10.1002/pmic.200900178] [PMID: 20049856]
[99]
Dong, X.; Dong, J.; Peng, G. Growth-inhibiting and apoptosis-inducing effects of tanshinone II A on human gastric carcinoma cells. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2007, 27(6), 706-709.
[http://dx.doi.org/10.1007/s11596-007-0623-y ] [PMID: 18231749]
[100]
Zhang, Z.; Gao, J.; Wang, Y.; Song, T.; Zhang, J.; Wu, G.; Zhang, T.; Du, G. Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding. Biochem. Pharmacol., 2009, 78(10), 1316-1322.
[http://dx.doi.org/10.1016/j.bcp.2009.06.110] [PMID: 19591811]
[101]
Zhang, Z.; Zhang, J.; Jin, L.; Song, T.; Wu, G.; Gao, J. Tanshinone IIA interacts with DNA by minor groove-binding. Biol. Pharm. Bull., 2008, 31(12), 2342-2345.
[http://dx.doi.org/10.1248/bpb.31.2342] [PMID: 19043224]
[102]
Shan, Y.F.; Shen, X.; Xie, Y.K.; Chen, J.C.; Shi, H.Q.; Yu, Z.P.; Song, Q.T.; Zhou, M.T.; Zhang, Q.Y. Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol. Sin., 2009, 30(11), 1537-1542.
[http://dx.doi.org/10.1038/aps.2009.139] [PMID: 19820721]
[103]
Jang, S.I.; Kim, H.J.; Kim, Y.J.; Jeong, S.I.; You, Y.O. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur. J. Pharmacol., 2006, 542(1-3), 1-7.
[http://dx.doi.org/10.1016/j.ejphar.2006.04.044] [PMID: 16797002]
[104]
Liu, W.; Zhou, J.; Geng, G.; Shi, Q.; Sauriol, F.; Wu, J.H. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A. J. Med. Chem., 2012, 55(2), 971-975.
[http://dx.doi.org/10.1021/jm2015292] [PMID: 22175694]
[105]
Zhang, B.; Shi, L.; Liu, S.; Guo, R. Tanshinone IIA derivative, and preparation and application of tanshinone IIA derivative. Patent number: CN104961794A, 2015.
[106]
Zhang, B.; Shi, L.; Liu, S.; Guo, R. Tanshinone IIA ethylidene imine phosphate derivative, as well as preparation method and application thereof. Patent number: CN105037427A, 2015.
[107]
Zhang, H.; Liu, W.; Liu, Z.; Ju, Y.; Xu, M.; Zhang, Y.; Wu, X.; Gu, Q.; Wang, Z.; Xu, J. Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening. Med. Chem. Comm., 2018, 9(6), 937-945.
[http://dx.doi.org/10.1039/C7MD00642J] [PMID: 30108982]
[108]
Gu, Q.; Zhang, H.; Xu, J.; Zhou, H. Indoleamine 2, 3- dioxygenase inhibitor containing tanshinone compound. Patent number: CN107698652A, 2018.
[109]
Zhao, Q.; Liu, J.; Ren, J.; Wu, X.; Yang, K. Tanshinone IIA derivative with IDO/TDO doubly-selective inhibitory activity. Patent number: CN109824753A, 2019.
[110]
Zhou, C.; Gan, L.; Zeng, L.; Zhu, Z. Amino acid tanshinone phenolic ester derivatives and preparation method thereof. Patent number: CN103980341A, 2014.
[111]
Bao, G.; Yuan, L.; He, X.; Liu, Z.; Peng, S.; Dong, Y.; Wang, H. Tanshinone IIA novel derivative, preparation method and applications thereof. Patent number: CN106243071A, 2016.
[112]
VanPatten, S.; Al-Abed, Y. High mobility group box-1 (HMGb1): current wisdom and advancement as a potential drug target. J. Med. Chem., 2018, 61(12), 5093-5107.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01136] [PMID: 29268019]
[113]
Guo, S.; Luo, W.; Liu, L.; Pang, X.; Zhu, H.; Liu, A.; Lu, J.; Ma, D-L.; Leung, C-H.; Wang, Y.; Chen, X. Isocryptotanshinone, a STAT3 inhibitor, induces apoptosis and pro-death autophagy in A549 lung cancer cells. J. Drug Target., 2016, 24(10), 934-942.
[http://dx.doi.org/10.3109/1061186X.2016.1157882] [PMID: 26904961]
[114]
Liu, X.; Chen, Z.; Yu, Z.; Zhou, Y.; Feng, T.; Zhou, Y.; Peng, L.; Tian, M.; Zhang, M. Tanshinone framework spliced bisindole or bispyrrole compound as well as preparation method and application thereof. Patent number: CN107188924A, 2017
[115]
Wu, Q.; Zheng, K.; Huang, X.; Li, L.; Mei, W. Tanshinone-IIA-based analogues of imidazole alkaloid act as potent inhibitors to block breast cancer invasion and metastasis in vivo. J. Med. Chem., 2018, 61(23), 10488-10501.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01018] [PMID: 30398868]
[116]
Mei, W. Application of tanshinone IIA derivatives in preparation of anti-gastric cancer drugs. Patent number: CN110123811A, 2019
[117]
Wang, D.; Zhang, W.; Wang, T.; Li, N.; Mu, H.; Zhang, J.; Duan, J. Unveiling the mode of action of two antibacterial tanshinone derivatives. Int. J. Mol. Sci., 2015, 16(8), 17668-17681.
[http://dx.doi.org/10.3390/ijms160817668] [PMID: 26263982]
[118]
Zeng, L.W.; Zhou, C.X.; Liu, J.D.; Liu, C.H.; Mo, J.X.; Hou, A.F.; Yao, W.; Wang, Z.Z.; Gan, L.S. Design, synthesis, and antimicrobial activities of new tanshinone IIA esters. Nat. Prod. Res., 2016, 30(23), 2662-2668.
[http://dx.doi.org/10.1080/14786419.2016.1138302] [PMID: 26829106]
[119]
Zhang, D.; Guo, J.; Zhang, M.; Liu, X.; Ba, M.; Tao, X.; Yu, L.; Guo, Y.; Dai, J. Oxazole-containing diterpenoids from cell cultures of Salvia miltiorrhiza and their anti-HIV-1 activities. J. Nat. Prod., 2017, 80(12), 3241-3246.
[http://dx.doi.org/10.1021/acs.jnatprod.7b00659] [PMID: 29185738]
[120]
Liu, W.; Yu, B.; Xu, G.; Xu, W-R.; Loh, M.L.; Tang, L-D.; Qu, C-K. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J. Med. Chem., 2013, 56(18), 7212-7221.
[http://dx.doi.org/10.1021/jm400474r] [PMID: 23957426]
[121]
Wang, J.; Huang, Z.; He, L.; He, L.; You, Q.; Li, Q. New application of tanshinone IIA derivatives as MAGL (monoacylglycerol lipase) inhibitor. Patent number: CN107118254A, 2017.
[122]
Wang, X.; Guo, J.; Ning, Z.; Wu, X. Discovery of a natural Syk inhibitor from chinese medicine through a docking-based virtual screening and biological assay study. Molecules, 2018, 23(12), 23.
[http://dx.doi.org/10.3390/molecules23123114] [PMID: 30487406]
[123]
Manzoni, L.; Zucal, C.; Maio, D.D.; D’Agostino, V.G.; Thongon, N.; Bonomo, I.; Lal, P.; Miceli, M.; Baj, V.; Brambilla, M.; Cerofolini, L.; Elezgarai, S.; Biasini, E.; Luchinat, C.; Novellino, E.; Fragai, M.; Marinelli, L.; Provenzani, A.; Seneci, P. Interfering with HuR-RNA interaction: design, synthesis and biological characterization of tanshinone mimics as novel, effective HuR Inhibitors. J. Med. Chem., 2018, 61(4), 1483-1498.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01176] [PMID: 29313684]
[124]
Provenzani, A.; D'Agostino, V.G.; Thongon, N.; Zucal, C.; Lal, P.; Adami, V.; Seneci, P.; Manzoni, L.; Marubelli, L.; Novellino, E.; Fragai, M.; Luchinat, C.; Cerofolinl, L.; Fuccio, C. Aza-tanshinone derivatives, process for their preparation and their use in therapy. Patent number: WO2017216732A1, 2017
[125]
Potter, P.M.; Wadkins, R.M. Carboxylesterases-detoxifying enzymes and targets for drug therapy. Curr. Med. Chem., 2006, 13(9), 1045-1054.
[http://dx.doi.org/10.2174/092986706776360969] [PMID: 16611083]
[126]
Hatfield, M.J.; Tsurkan, L.G.; Hyatt, J.L.; Edwards, C.C.; Lemoff, A.; Jeffries, C.; Yan, B.; Potter, P.M. Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza (“Danshen”). J. Nat. Prod., 2013, 76(1), 36-44.
[http://dx.doi.org/10.1021/np300628a] [PMID: 23286284]
[127]
Hatfield, M.J.; Binder, R.J.; Gannon, R.; Fratt, E.M.; Bowling, J.; Potter, P.M. Potent, irreversible inhibition of human carboxylesterases by tanshinone anhydrides isolated from Salvia miltiorrhiza (“Danshen”). J. Nat. Prod., 2018, 81(11), 2410-2418.
[http://dx.doi.org/10.1021/acs.jnatprod.8b00378] [PMID: 30351923]
[128]
Binder, R.J.; Hatfield, M.J.; Chi, L.; Potter, P.M. Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors. Eur. J. Med. Chem., 2018, 149, 79-89.
[http://dx.doi.org/10.1016/j.ejmech.2018.02.052] [PMID: 29499489]
[129]
Ding, C.; Chen, H.; Liang, B.; Jiao, M.; Liang, G.; Zhang, A. Biomimetic synthesis of the natural product salviadione and its hybrids: discovery of tissue-specific anti-inflammatory agents for acute lung injury. Chem. Sci. (Camb.), 2019, 10(17), 4667-4672.
[http://dx.doi.org/10.1039/C9SC00086K] [PMID: 31123577]
[130]
Yang, Z.; Mei, W.; Ma, L.; Zhao, Z.; Luo, S.; Zhou, L. Tanshinone IIA derivative TAN20, preparation method and application thereof. CN110330545A, 2019.
[131]
Ma, X.H.; Ma, Y.; Tang, J.F.; He, Y.L.; Liu, Y.C.; Ma, X.J.; Shen, Y.; Cui, G.H.; Lin, H.X.; Rong, Q.X.; Guo, J.; Huang, L.Q. The Biosynthetic Pathways of Tanshinones and Phenolic Acids in Salvia miltiorrhiza. Molecules, 2015, 20(9), 16235-16254.
[http://dx.doi.org/10.3390/molecules200916235] [PMID: 26370949]
[132]
Gao, W.; Sun, H.X.; Xiao, H.; Cui, G.; Hillwig, M.L.; Jackson, A.; Wang, X.; Shen, Y.; Zhao, N.; Zhang, L.; Wang, X.J.; Peters, R.J.; Huang, L. Combining metabolomics and transcriptomics to characterize tanshinone biosynthesis in Salvia miltiorrhiza. BMC Genomics, 2014, 15, 73.
[http://dx.doi.org/10.1186/1471-2164-15-73] [PMID: 24467826]
[133]
Xu, J.; Zhang, C.; Shi, X.; Li, J.; Liu, M.; Jiang, W.; Fang, Z. Efficacy and safety of sodium tanshinone IIA sulfonate injection on hypertensive nephropathy: a systematic review and meta-analysis. Front. Pharmacol., 2019, 10, 1542-1555.
[http://dx.doi.org/10.3389/fphar.2019.01542] [PMID: 31920681]

Rights & Permissions Print Cite
Article Metrics
105
1
© 2024 Bentham Science Publishers | Privacy Policy